Dupixent & Libtayo fuel growth despite volatility & Eylea biosimilar risks; margins to recover. Click for an REGN update.
Sumitomo Corporation remains a 'Buy', as I see the expected uptrend in ROIC and ROE justifying a higher P/B multiple. Management targets a 100bps ROIC expansion over the next five years at the recent ...
Carnival Corporation & plc’s CCL latestearnings callhighlights a potential inflection point in its long-term profitability. Management reported return on invested capital (“ROIC”) above 13% in fiscal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results